Monitoring the amyloid beta-peptide in vivo--caveat emptor

Drug Discovery Today
Paul W Thompson, Andrew Lockhart

Abstract

As a wave of 'disease modifying' (DM) therapies for Alzheimer's disease (AD) progresses towards the later stages of clinical development, an evaluation of our ability to measure relevant pharmacodynamic effects of such therapies is warranted. Reducing accumulation of amyloid beta (Abeta)-peptide in the brain parenchyma is the primary objective of most current DM approaches. Although a number of methods are available to measure Abeta in blood, cerebrospinal fluid (CSF) and the cerebrum, putative DM-induced changes in the levels of the peptides may not be fully captured, and the reasons for any such changes are not fully understood. Additional candidate biofluid (tau and isoprostanes) and imaging (MRI, FDG-PET) measures may provide alternative supporting evidence of drug activity and subsequent clinical efficacy in patient populations.

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Oct 1, 1991·Trends in Pharmacological Sciences·J Hardy, D Allsop
Mar 1, 1983·Annals of Internal Medicine·M E PhelpsJ C Mazziotta
Mar 20, 1998·Annals of Neurology·V P PrasherA C Butler
Apr 20, 1999·Biochemical and Biophysical Research Communications·Y M KuoA E Roher
Feb 19, 2000·Biochemical and Biophysical Research Communications·Y M KuoA E Roher
Dec 29, 2000·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·H VandersticheleE Vanmechelen
Nov 22, 2001·JAMA : the Journal of the American Medical Association·D H SilvermanM E Phelps
Mar 27, 2003·Trends in Molecular Medicine·Jean-Cosme DodartSteven M Paul
Jun 5, 2003·Dementia and Geriatric Cognitive Disorders·Annika OlssonKaj Blennow
Dec 4, 2003·Neurobiology of Aging·Salvatore OddoFrank M LaFerla
Apr 23, 2004·Brain : a Journal of Neurology·Francis EustacheBéatrice Desgranges
Feb 8, 2005·Proceedings of the National Academy of Sciences of the United States of America·Dimitra G GeorganopoulouChad A Mirkin
Apr 6, 2005·Trends in Neurosciences·Berislav V Zlokovic
Apr 23, 2005·Clinical Chemistry·Niki S M SchoonenboomMarinus A Blankenstein
Apr 27, 2005·Annals of Neurology·Murray GrossmanVirginia M-Y Lee
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
May 11, 2005·Neurology·N C FoxUNKNOWN AN1792(QS-21)-201 Study
Nov 1, 2005·Journal of the Neurological Sciences·Kun TangRoger N Rosenberg
Jun 2, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Atul DeshpandeJorge Busciglio
Jun 27, 2006·Nature Medicine·Randall J BatemanDavid M Holtzman
Aug 1, 2006·Lancet·Kaj BlennowHenrik Zetterberg
Aug 25, 2006·Current Neurology and Neuroscience Reports·Eric R SiemersPatrick C May
Aug 31, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·J Randall SlemmonPeter Seubert
Oct 19, 2006·Seminars in Neurology·R Scott Turner
Nov 2, 2006·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Robert D BellBerislav V Zlokovic
Nov 30, 2006·Drug Discovery Today·Andrew Lockhart
Jan 26, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·E N KapakiD Vassilopoulos
Feb 9, 2007·Journal of Neurochemistry·Dominic M Walsh, Dennis J Selkoe
Feb 21, 2007·Dementia and Geriatric Cognitive Disorders·A H SimonsenK Blennow

❮ Previous
Next ❯

Citations

Apr 12, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Giorgio Gelosa, David J Brooks
Jun 11, 2011·International Journal of Alzheimer's Disease·Cheryl A LuisMichael Mullan
Sep 21, 2013·Drug Discovery Today. Technologies·Bart LaurijssensAnisur Rahman
May 10, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jeffrey L Cummings
Jan 7, 2010·Journal of Neurochemistry·Minna A KorolainenTuula Pirttilä

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Brain Aging

Here is the latest research on intrinsic and extrinsic factors, as well as pathways and mechanisms that underlie aging in the central nervous system.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Aging Epidemiology

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Cell Aging (Keystone)

This feed focuses on cellular aging with emphasis on the mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Cell Aging

This feed focuses on cellular aging with emphasis on mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.